Copyright © 2006 by American Society of Health-System Pharmacists
Applying antimicrobial pharmacodynamics to resistant gram-negative pathogensMARC H. SCHEETZ, PHARM.D., is Infectious Diseases Fellow; and KRISTIN M. HURT, PHARM.D., is Infectious Diseases Specialty Resident, Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL. GARY A. NOSKIN, M.D., is Associate Professor of Medicine, Department of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago. CATHERINE M. OLIPHANT, PHARM.D., is Associate Professor of Pharmacy Practice, College of Pharmacy, Idaho State University, Boise. Address correspondence to Dr. Scheetz at the Department of Pharmacy, Northwestern Memorial Hospital, 251 East Huron Street, Feinberg Pavilion LC-700, Chicago, IL 60611 (mscheetz{at}nmh.org).
Summary. Multidrug-resistant pathogens are being isolated with increasing frequency, while the production of novel agents to circumvent resistance has slowed to a near halt. Hence, antimicrobial adjustment based on drug pharmacokinetic and pharmacodynamic properties has moved to the forefront of treatment. Pharmacodynamic principles for major classes of antimicrobials are reviewed, and the use of susceptibility reports to optimize pharmacodynamics to treat gram-negative infections is described. The need for the application of antimicrobial pharmacodynamics continues to grow as resistance to the agents becomes more common. Susceptibility reports, including antibiograms, and their limitations are briefly discussed. The resistance profiles of the ß-lactams (including carbapenems), aminoglycosides, fluoroquinolones, tetracyclines and glycylcyclines, and the polymyxins are reviewed, and the pharmacodynamic optimization of these profiles is explored.
Conclusion. Various mechanisms account for resistance of bacteria to antibiotics. The appropriate use of pharmacokinetics and pharmacodynamics can guide antibiotic therapy and enhance the likelihood of success.
Index terms: Aminoglycosides; Antiinfective agents; Carbapenems; Drug use; Glycylcyclines; Methodology; Pharmacodynamics; Pharmacokinetics; Polymyxins; Quinolones; Rational therapy; Resistance; Tetracyclines
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||